Ads
related to: multiple myeloma b cell malignancy treatment- Treatment Schedule
Learn How This Treatment Is Given
See the Infusion Schedule
- Phase 3 Trials
See Study Results
From the Latest Trial
- Resources
Download Helpful Resources
for Patients and Caregivers
- Safety Information
Read Safety Information
for Patients and Caregivers
- Treatment Schedule
Search results
Results From The WOW.Com Content Network
A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107] There are two types of stem cell transplants to treat multiple myeloma. [108] In autologous hematopoietic stem-cell transplantation (ASCT) – the patient's stem cells are collected from the patient's blood. The patient is given high-dose ...
Serum B-cell maturation antigen (sBCMA) is the cleaved form of B-cell maturation antigen (BCMA), found at low levels in the serum of normal patients and generally elevated in patients with multiple myeloma (MM). [5] Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment. [6] [7]
Teclistamab, sold under the brand name Tecvayli, is a human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma. [8] It is a bispecific antibody that targets the CD3 receptor expressed on the surface of T-cells and B-cell maturation antigen (), which is expressed on the surface of malignant multiple myeloma B-lineage cells.
ALLO-715 is a CAR-T therapy by Allogene Therapeutics that targets B-cell maturation antigen (BCMA). [19] As of June 2021, it is undergoing clinical trials for the treatment of multiple myeloma. [20] On 21 April 2021, the FDA granted Regenerative Medicine Advanced Therapy status to ALLO-715. [21]
Belantamab mafodotin is a humanized IgG1κ monoclonal antibody against the B-cell maturation antigen (BCMA) conjugated with a cytotoxic agent, maleimidocaproyl monomethyl auristatin F (mcMMAF). [3] The antibody-drug conjugate binds to BCMA on myeloma cell surfaces causing cell cycle arrest and inducing antibody-dependent cellular cytotoxicity. [3]
Elranatamab, sold under the brand name Elrexfio, is a medication used for the treatment of multiple myeloma. [8] [12] Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. [8] [12] [13] [14] Elranatamab is given by subcutaneous injection. [8] [12]
Ads
related to: multiple myeloma b cell malignancy treatment